Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of ST2 and NT-proBNP as Cardiac Biomarkers in Dogs With Chronic Mitral Valve Disease

  • Kim, Jung-Kook (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Jun-Seok (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • Received : 2018.01.18
  • Accepted : 2018.03.29
  • Published : 2018.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.

Keywords

References

  1. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 1142-1150. https://doi.org/10.1111/j.1939-1676.2009.0392.x
  2. Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, Cano L, Gonzalez B, Diez C, Pascual T, Elosua R, Lupon J. Combined use of high-sensitiviy ST2 and NT-proBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012; 14: 32-38. https://doi.org/10.1093/eurjhf/hfr156
  3. Boswood A. Biomarkers in cardiovascular disease: Beyond natriuretic peptideds. J Vet Cardiol 2009; 11: S23-S32. https://doi.org/10.1016/j.jvc.2009.01.003
  4. Viller E and Ristic J. Laboratory evaluation of cardiac disease. In: BSAVA Manual of canine and feline clinical pathology, 3th ed. BSAVA. 2016: 389-397.
  5. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL jr. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and Beta Blocker Therapy in Chronic Heart Failure. Circ Heart Fail 2013; 6: 1206-1213. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000457
  6. Gimenes AM, Castro JR, Mantovani MM, Duarte CN, Petrus LC, Ueda Y, Goldfeder GT, Larsson MH, Schwartz DS. Soluble ST2 biomarker in heart failure secondary to chronic mitral valve disease in dogs. 2017 ACVIM.
  7. Grande D, Leone M, Rizzo C, Terlizzes P, Parisi G, Gioia MI, Leopizzi T, Segreto A, Guida P, Romito R, Ciccone MM, Serio FD, Iacoviello M. A multiparametric approach based on NT-proBNP, ST2, and Galectin3 for stratifying one year prognosis of chronic heart failure outpatients. J Cardiovasc Dev Dis 2017; 4(9).
  8. Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K, Elliott J. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012; 26: 302e11. https://doi.org/10.1111/j.1939-1676.2012.00894.x
  9. Lee SG and Hyun CB. Evaluation of plasma concentration in dogs with chronic mitral valve insufficiency. J Vet Clin 2013; 30: 151-158.
  10. Ljungvall. I, Hoglund K, Tidholm A, Olsen LH, Boragrelli M, Venge P, Haggstrom J. Cardiac Troponin I Is Associated with Severity of Myxomatous Mitral Valve disease, age, and C-Reactive protein in dogs. J Vet Intern Med 2010; 24: 153-159. https://doi.org/10.1111/j.1939-1676.2009.0428.x
  11. Nayak SB, Sawh D, Scott B, Sears V, Seebalack K, Seenath M, Seepaulsingh P, Seepersad S, Seetahal V, Ramsaroop K. Evaluation of the efficacy of ST2 and NT-proBNP in the diagnosis and prediction of shore-term progrnosis in heart failure with reduced ejection fraction. IJPCR 2017; 9: 309-312.
  12. Nelson RW and Couto CG. Acquired valvular and endocardial disease. In: Small Animal Internal Medicine, 5th ed. Elsevier. 2013: 115-120.
  13. Oyama MA, FoxPR, Rush JE, Rozanski EA, Lesser M. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008; 232: 1496-1503. https://doi.org/10.2460/javma.232.10.1496
  14. Oyama MA, Boswood A, Connolly DJ, Ettinger SJ, Fox PR, Gordon SG, Rush JE, Sisson DD, Stepien RL, Wess G. Clinical usefulness of an assay for measurement of circulating Nterminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease. J Am Vet Med Assoc 2013; 243: 71e82. https://doi.org/10.2460/javma.243.1.71
  15. Pascual-Figal DA, Januzzi JL. The biology of ST2: The international ST2 consensus panel. Am J Cardiol 2015; 115 [7 suppl]: 3B-7B. https://doi.org/10.1016/j.amjcard.2015.01.034
  16. Takemura N, Toda N, Miyagawa, Asano K, Tejima K, Kanno N, Arisawa K, Kurita T, Nunokawa K, Hirakawa A, Tanaka S, Hirose H. Evaluation of plasma N-terminal probrain natriuretic peptide (NT-proBNP) concentration in dogs with mitral valve insufficiency. J Vet Med Sci 2009; 71: 925-929. https://doi.org/10.1292/jvms.71.925
  17. Vilacorta H, Maisel AS. Soluble ST2 testing: A promising biomarker in the management of Heart failure. Arq Bras Cardiol. 2016; 106: 145-152.
  18. Wolf J, Gerlach N, Weber K, Klima A, Wess G. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol 2012; 14: 399-408. https://doi.org/10.1016/j.jvc.2012.05.005
  19. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implicatioin on interpretation of test results. Am Heart J 2013; 165: 995-999. https://doi.org/10.1016/j.ahj.2013.02.029